SGM
GENB

Seven Grand Managers’s Generate Biomedicines GENB Stock Holding History

Seven Grand Managers’s Portfolio GENB Stock Details GENB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.11M Hold
125,000
– – 0.08% 140
2026
Q1 		$1.56M Buy
+125,000
New +$1.53M 0.1% 130

Other funds holding GENB

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $170M AUM 34.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Seven Grand Managers's GENB Position: Q2 2026 in Review

Seven Grand Managers held its Generate Biomedicines (GENB) position steady in Q2 2026 at 125,000 shares worth $2.11M. The position accounts for 0.08% of the portfolio, ranked #140.

Seven Grand Managers first reported a position in GENB in Q1 2026 and has held it in 2 quarters since. 86 funds tracked by Wall St. Rank hold GENB as of Q2 2026.

  • Seven Grand Managers held 125,000 shares of Generate Biomedicines worth $2.11M as of Q2 2026.
  • Seven Grand Managers left its Generate Biomedicines share count unchanged in Q2 2026.
  • Generate Biomedicines made up 0.08% of Seven Grand Managers's portfolio in Q2 2026, its #140 holding.
  • Seven Grand Managers first reported a position in Generate Biomedicines in Q1 2026 and has held it in 2 quarters since.
  • 86 funds tracked by Wall St. Rank held Generate Biomedicines as of Q2 2026.

Based on Seven Grand Managers's 13F filing for Q2 2026, filed 14 Aug 2026.